OTCMKTS:VYNT Vyant Bio (VYNT) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free VYNT Stock Alerts $0.19 +0.01 (+7.78%) (As of 12/29/2023) Add Compare Share Share Today's Range$0.18▼$0.2050-Day Range$0.19▼$0.1952-Week Range$0.14▼$1.58Volume19,100 shsAverage Volume161,822 shsMarket Capitalization$1.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Get Vyant Bio alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Vyant Bio Stock (OTCMKTS:VYNT)Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.Read More VYNT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYNT Stock News HeadlinesApril 19, 2024 | americanbankingnews.comVyant Bio (OTCMKTS:VYNT) Shares Up 7.8%December 26, 2023 | msn.comVyant Bio files Certificate of Dissolution with State of DelawareApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. December 19, 2023 | morningstar.comVyant Bio Inc VYNTNovember 11, 2023 | finanznachrichten.deVyant Bio, Inc.: Vyant Bio Provides Update on Winddown ActivitiesNovember 10, 2023 | msn.comVyant Bio expects to start liquidation payments in Q4 2024November 10, 2023 | finance.yahoo.comVyant Bio Provides Update on Winddown ActivitiesNovember 1, 2023 | finanznachrichten.deVyant Bio, Inc.: Vyant Bio Announces Stockholder Approval of Plan of DissolutionApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. November 1, 2023 | msn.comVyant Bio shareholders approve plan to dissolve companyNovember 1, 2023 | finance.yahoo.comVyant Bio Announces Stockholder Approval of Plan of DissolutionOctober 26, 2023 | finance.yahoo.comLab Notes: Philadelphia health care investment firm closes two funds valued at over $500MOctober 25, 2023 | finanznachrichten.deVyant Bio, Inc.: Vyant Bio Announces Completion of StemoniX Asset SaleOctober 24, 2023 | finance.yahoo.comVyant Bio Announces Completion of StemoniX Asset SaleOctober 19, 2023 | finance.yahoo.comVyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of StockholdersOctober 11, 2023 | finance.yahoo.comVyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of StockholdersSeptember 30, 2023 | finanznachrichten.deVyant Bio, Inc.: Vyant Bio Announces Adjournment of Special Meeting of StockholdersSeptember 20, 2023 | finance.yahoo.comVyant Bio Announces Adjournment of Special Meeting of StockholdersAugust 21, 2023 | yahoo.comMedicare patients took unnecessary genetic cancer tests in man’s $463M scheme, feds sayAugust 21, 2023 | washingtonpost.com‘Asian glow’ from alcohol isn’t just a discomfort. It’s a severe warning.August 18, 2023 | msn.comGene that vastly increases chance of breast cancer found by scientistsAugust 17, 2023 | msn.comThe dangerous gene that vastly increases your chance of breast cancerAugust 9, 2023 | msn.comAI Can Find Cancer’s Origin: StudyJuly 18, 2023 | benzinga.comGenprex – FDA Grants Fast Track Approval For Promising New Cancer Gene TherapyJuly 17, 2023 | bizjournals.comVyant Bio enters into deal to sells its microBrain assets for $2.25MJuly 17, 2023 | finance.yahoo.comAxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX AssetsJuly 6, 2023 | msn.comGene editing helped crack a 100-year-old mystery about cancerSee More Headlines Receive VYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolOTCMKTS:VYNT CUSIPN/A CIK1349929 Webstemonix.com Phone(201) 479-1357Fax201-528-9201Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,690,000.00 Net Margins-3,474.81% Pretax Margin-3,281.86% Return on Equity-151.82% Return on Assets-97.14% Debt Debt-to-Equity Ratio0.04 Current Ratio2.86 Quick Ratio2.86 Sales & Book Value Annual Sales$670,000.00 Price / Sales1.83 Cash FlowN/A Price / Cash FlowN/A Book Value$1.69 per share Price / Book0.11Miscellaneous Outstanding Shares6,330,000Free Float5,724,000Market Cap$1.23 million OptionableNot Optionable Beta1.73 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Andrew D.C. LaFrence CPA (Age 60)President, CEO & CFO Comp: $407.4kMr. Yung-Ping Yeh M.B.A. (Age 47)M.S., P.M.P., Co-Founder & Director Comp: $22.5kKey CompetitorsCannLabsOTCMKTS:CANLZicixOTCMKTS:ZICXAclarionNASDAQ:ACONInvitaeNYSE:NVTABionik LaboratoriesOTCMKTS:BNKLView All Competitors VYNT Stock Analysis - Frequently Asked Questions How have VYNT shares performed in 2024? Vyant Bio's stock was trading at $0.1940 on January 1st, 2024. Since then, VYNT stock has increased by 0.0% and is now trading at $0.1940. View the best growth stocks for 2024 here. How were Vyant Bio's earnings last quarter? Vyant Bio, Inc. (OTCMKTS:VYNT) released its earnings results on Thursday, November, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.75). The firm had revenue of $1.51 million for the quarter, compared to the consensus estimate of $2.19 million. Vyant Bio had a negative trailing twelve-month return on equity of 151.82% and a negative net margin of 3,474.81%. During the same quarter in the previous year, the firm posted ($2.90) EPS. When did Vyant Bio's stock split? Vyant Bio shares reverse split before market open on Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Vyant Bio? Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:VYNT) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vyant Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
